About Psilos
Investors In The Healthcare Economy

HISTORY

Psilos Group was founded in 1998 by Dr. Albert Waxman. The Psilos team came together during the period 1998-1999 and has worked together as a cohesive unit since that time with several professional relationships dating back nearly 20 years. Today the partnership includes four Managing Members: Dr. Albert Waxman, Stephen Krupa, Joseph Riley and David Eichler.

Psilos has, since its first day, sought to establish a perpetual organization that is considered one of the premier healthcare investment firms. Towards that end, the Psilos team has consistently delivered strong healthcare investment returns, which we believe to be the culmination of our fifteen years together applying our unique investment model with the same team and the same rigor.

Psilos has successfully deployed three venture funds representing over $580 million in committed capital.

Tom Trotter, AngioScore’s President &
CEO, discusses how the AngioSculpt significantly alters the landscape for treating both peripheral arterial disease (PAD) and coronary artery disease (CAD).

AngioScore develops, manufactures and markets the AngioSculpt Scoring Balloon Catheter for both the coronary and peripheral interventional markets. These markets represent a worldwide opportunity of over $2 billion. AngioSculpt combines a semi-compliant balloon with an innovative nitinol scoring element that uniquely cuts through plaque to open the target artery. The catheter is designed to address the limitations of conventional angioplasty balloon catheters, improve the deployment of drug-eluting stents through enhanced vessel preparation, and to provide safe and effective treatment options for complex and difficult-to-open vessels in the more than 4 million angioplasty procedures that are performed annually.